Search results for "Retrospective Cohort Study"

showing 10 items of 1452 documents

Expression of programmed death ligand-1 (PD-L1) in metastatic and postchemotherapy viable testicular germ cell tumors.

2020

Abstract Introduction Chemotherapy for testicular germ cell tumors (GCT) is highly effective, with few patients who do not respond. Clinical studies to evaluated novel treatments are challenging given the rarity of these patients. Therefore, we sought to evaluate PD-L1 staining on metastatic and postchemotherapy viable testicular GCTs as a surrogate for potential benefit for immunotherapy targeting the PD-1/PD-L1 axis. Methods Ethics research committee approval for this retrospective study was obtained by four participating institutions (CHU de Quebec, St. Joseph's Health Care, Halifax Health Science Centre, Johannes Gutenberg University). Patients with viable metastatic testicular GCTs pat…

OncologyAdultMalemedicine.medical_specialtyUrologymedicine.medical_treatment030232 urology & nephrologyB7-H1 Antigen03 medical and health sciencesYoung Adult0302 clinical medicineTesticular NeoplasmsInternal medicinemedicineHumansOrchiectomyRetrospective StudiesChemotherapybusiness.industryChoriocarcinomaRetrospective cohort studySeminomaImmunotherapyNeoplasms Germ Cell and Embryonalmedicine.diseaseOncology030220 oncology & carcinogenesisImmunohistochemistryTeratomabusinessUrologic oncology
researchProduct

Brain-derived neurotrophic factor (Val66Met) polymorphism does not influence recovery from a post-traumatic vegetative state: a blinded retrospective…

2012

Brain-derived neurotrophic factor (BDNF) is a neurotrophin that influences neuronal plasticity throughout life. Emergence from a vegetative state (VS) after a traumatic brain injury (TBI) implies that the brain undergoes plastic changes. A common polymorphism in the BDNF gene—BDNF Val66Met (referred to herein as BDNFMet)—impairs cognitive function in healthy subjects. The aim of this study was to determine whether the BDNFMet polymorphism plays a role in the recovery of consciousness and cognitive functions in patients in a VS after a TBI. Fifty-three patients in a VS 1 month after a TBI were included in the study and genotyped for the BDNFMet polymorphism. Scores of levels of cognitive fun…

OncologyAdultMalemedicine.medical_specialtydisorders of consciousneAdolescentGenotypeTraumatic brain injuryPolymorphism Single Nucleotidevegetative stateYoung AdultNeurotrophic factorsInternal medicineNeuroplasticitymedicineHumansYoung adultPsychiatryRetrospective StudiesBrain-derived neurotrophic factorbiologytraumatic brain injuryBrain-Derived Neurotrophic FactorPersistent Vegetative Statelevels of cognitive functioninggenetic factorRetrospective cohort studyCognitionRecovery of FunctionMiddle Agedmedicine.diseasenervous systemBrain Injuriesbiology.proteinFemaleNeurology (clinical)PsychologyPolymorphism Restriction Fragment LengthNeurotrophinJournal of neurotrauma
researchProduct

Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicente…

2006

Abstract Background Carboplatin/paclitaxel is the chemotherapy of choice for advanced ovarian cancer, both in first line and in platinum-sensitive recurrence. Although a significant proportion of patients have some neurotoxicity during treatment, the long-term outcome of chemotherapy-induced neuropathy has been scantly studied. We retrospectively assessed the prevalence of residual neuropathy in a cohort of patients in clinical remission after first-line carboplatin/paclitaxel for advanced ovarian cancer. Methods 120 patients have been included in this study (101 participating in a multicentre phase III trial evaluating the efficacy of consolidation treatment with topotecan, and 19 treated …

OncologyAdultmedicine.medical_specialtyCancer ResearchTime Factorsendocrine system diseasesPaclitaxelmedicine.medical_treatmentlcsh:RC254-282Severity of Illness IndexCarboplatinchemistry.chemical_compoundMedian follow-upInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineGeneticsHumansAgedRetrospective StudiesOvarian NeoplasmsChemotherapybusiness.industryCancerPeripheral Nervous System DiseasesRetrospective cohort studyMiddle Agedmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensCarboplatinfemale genital diseases and pregnancy complicationsClinical trialchemistryOncologyTopotecanFemalebusinessOvarian cancerTopotecanmedicine.drugResearch Article
researchProduct

Breast cancer subtypes can be determinant in the decision making process to avoid surgical axillary staging: A retrospective cohort study.

2015

Abstract Introduction The need for performing axillary lymph-node dissection in early breast cancer when the sentinel lymph node (SLN) is positive has been questioned in recent years. The purpose of this study was to identify a low-risk subgroup of early breast cancer patients in whom surgical axillary staging could be avoided, and to assess the probability of having a positive lymph-node (LN). Methods We evaluated the cohort of 612 consecutive women affected by early breast cancer. We considered age, tumor size, histological grade, vascular invasion, lymphatic invasion and cancer subtype (Luminal A, Luminal B HER-2+, Luminal B HER-2−, HER-2+, and Triple Negative) as variables for univariat…

OncologyAdultmedicine.medical_specialtyLymphovascular invasionReceptor ErbB-2Sentinel lymph nodeClinical Decision-Makingbreast cancer axillary surgery sentinel lymph node biopsy adjuvant treatment biological prognostic factors.Breast NeoplasmsTriple Negative Breast NeoplasmsCohort StudiesBreast cancerInternal medicineMedicineHumansNeoplasm InvasivenessSettore SECS-S/05 - Statistica SocialeLymph nodeAgedNeoplasm StagingRetrospective StudiesGynecologyAged 80 and overbusiness.industrySentinel Lymph Node BiopsyAge FactorsCancerRetrospective cohort studyGeneral MedicineOdds ratioMiddle Agedmedicine.diseaseSettore MED/18 - Chirurgia GeneraleExact testmedicine.anatomical_structureLymphatic MetastasisAxillaLymph Node ExcisionSurgeryFemalebusinessInternational journal of surgery (London, England)
researchProduct

Target therapy in HER2-overexpressing breast cancer patients.

2011

The development of new therapeutic strategies, such as monoclonal antibodies directed against human epidermal growth factor receptor-2 (HER2), has offered new hopes for women with early breast cancer whose tumors overexpress HER2. We retrospectively analyzed the population-based data of Breast Cancer Registry of Palermo in 2004-2006, and selected 1401 invasive breast cancer cases, nonmetastatic at diagnosis, having HER2/neu oncogene expression determined. We have correlated this information to age, tumor stage at diagnosis (TNM), nodal involvement, and receptor status (ER and PgR). Survival analysis was conducted dividing the patients in two different groups according to date of diagnosis: …

OncologyAdultmedicine.medical_specialtyReceptor StatusReceptor ErbB-2PopulationAntineoplastic AgentsBreast NeoplasmsKaplan-Meier EstimateAntibodies Monoclonal HumanizedBiochemistryBreast cancerTrastuzumabInternal medicineGeneticsmedicineHumansMolecular Targeted Therapyskin and connective tissue diseaseseducationMolecular BiologySurvival analysisAgedNeoplasm StagingRetrospective StudiesAged 80 and overeducation.field_of_studybiologybusiness.industryAntibodies MonoclonalRetrospective cohort studyMiddle AgedTrastuzumabmedicine.diseasePrognosisMonoclonalbiology.proteinMolecular MedicineFemaleAntibodybusinessBiotechnologymedicine.drugOmics : a journal of integrative biology
researchProduct

Clinical outcome of recurrent locally advanced cervical cancer (LACC) submitted to primary multimodality therapies

2015

Abstract Objectives Recurrence of disease represents a clinical challenge in cervical cancer patients, especially when all available treatment modalities have been used in the primary setting. The aim of this study was to analyze the patterns of recurrence and their association with clinical outcome in locally advanced cervical cancer (LACC) patients submitted to primary chemoradiation (CTRT) followed by radical surgery (RS). Methods This study was conducted on 364 LACC patients treated with CTRT plus RS since January 1996 to July 2012. For each relapse, information on date of clinical/pathological recurrence, and pattern of disease presentation were retrieved. Post-relapse survival (PRS) w…

OncologyAdultmedicine.medical_specialtyUterine Cervical Neoplasmrecurrent cervical cancerPrognosimedicine.medical_treatmentUterine Cervical NeoplasmsDiseaseObstetrics and gynaecologyRetrospective StudieInternal medicinemedicineHumansRadical surgeryChemoradiation; Post-relapse survival; Prognosis; Radical hysterectomy; Recurrent cervical cancer; Adult; Chemoradiotherapy; Adjuvant; Female; Humans; Neoadjuvant Therapy; Neoplasm Recurrence; Local; Retrospective Studies; Survival Analysis; Treatment Outcome; Uterine Cervical NeoplasmschemoradiationSurvival analysisNeoadjuvant therapyAdjuvantRetrospective StudiesSettore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIACervical cancerbusiness.industrypost-relapse survivalObstetrics and GynecologyRetrospective cohort studyChemoradiotherapy AdjuvantChemoradiotherapymedicine.diseaseSurvival AnalysisNeoadjuvant TherapySurgeryLog-rank testTreatment OutcomeNeoplasm RecurrenceSettore MED/40 - GINECOLOGIA E OSTETRICIAOncologyLocalradical hysterectomyFemaleSurvival AnalysiprognosisNeoplasm Recurrence LocalbusinessHuman
researchProduct

Serum microRNA profiles as prognostic/predictive markers in the multimodality therapy of locally advanced adenocarcinomas of the gastroesophageal jun…

2014

Neoadjuvant multimodality treatment is frequently applied to improve the poor prognosis of locally advanced adenocarcinomas of the gastroesophageal junction. This study aimed to asses if serum microRNA profiles are useable as response indicators in this therapeutic setting. Fifty patients with locally advanced adenocarcinomas of the gastroesophageal junction were included in the study. All patients received neoadjuvant therapy and subsequently underwent surgical resection. Histomorphologic regression was defined as major histopathological response when resected specimens contained less than 10% vital residual tumor cells. Circulating RNA was isolated from pretherapeutic/post-neoadjuvant blo…

OncologyCancer ResearchPathologymedicine.medical_specialtyMicroarraybusiness.industrymedicine.medical_treatmentRetrospective cohort studyMultimodality TherapyGene expression profilingBlood serumOncologyInternal medicinemicroRNAMedicinebusinessNeoadjuvant therapyChemoradiotherapyInternational Journal of Cancer
researchProduct

Peritoneal Carcinomatosis and Multi-Organ Metastases are Prognostic Factors in Colorectal Cancer: A Retrospective Analysis

2016

 Background: Peritoneal carcinomatosis and multi-organ metastases might be prognostic factors in patients with advanced colorectal cancer and inoperable metastases at diagnosis. Methods: A retrospective study was performed to examine the relationship between patient clinical characteristics and prognosis in patients with colorectal cancer and indication for first-line systemic chemotherapy. Results: One hundred and twelve patients were accrued. According to univariate analysis, peritoneal carcinomatosis, lack of primary tumour resection and multi-organ metastases were associated with poor overall survival. According to multivariate analysis, patients with peritoneal carcinomatosis and patie…

OncologyCancer ResearchUnivariate analysismedicine.medical_specialtyChemotherapyMultivariate analysisColorectal cancerbusiness.industrymedicine.medical_treatmentRetrospective cohort studymedicine.diseaseMulti organPeritoneal carcinomatosisOncologyInternal medicinemedicineRetrospective analysisbusinessJournal of Analytical Oncology
researchProduct

The Risk of Toxicities from Trastuzumab, Alone or in Combination, in an Elderly Breast Cancer Population

2013

<b><i>Background:</i></b> Breast cancer in the elderly is associated with high recurrence and death rates, due mostly to undertreatment. Human epidermal growth factor receptor type 2 (HER2) overexpression is infrequent in older patients. Trastuzumab-based chemotherapy is often withheld from elderly patients because of its cardiotoxicity. <b><i>Patients and Methods:</i></b> Medical records of consecutive HER2-positive breast cancer patients aged ≥70 years old treated between 2005 and 2010 in the participating centers were retrospectively reviewed. All patients underwent multidimensional geriatric assessment (MGA). <b><i>Results:<…

OncologyCancer Researchmedicine.medical_specialtyAnthracyclineSettore MED/06 - Oncologia MedicaReceptor ErbB-2medicine.medical_treatmentPopulationAntineoplastic AgentsBreast NeoplasmsAntibodies Monoclonal HumanizedVentricular Function LeftBreast cancer; Elderly patients; Human epidermal growth factor receptor type 2; TrastuzumabBreast cancerBreast cancerTrastuzumabInternal medicinemedicineHumansAdverse effecteducationGeriatric AssessmentAgedRetrospective StudiesAged 80 and overChemotherapyCardiotoxicityeducation.field_of_studybusiness.industryRetrospective cohort studyGeneral MedicineTrastuzumabmedicine.diseaseHuman epidermal growth factor receptor type 2OncologyFemalebusinessElderly patientmedicine.drugOncology
researchProduct

The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients

2013

Background: ER þ/HER2 � breast cancers have a proclivity for late recurrence. A personalised estimate of relapse risk after 5 years of endocrine treatment can improve patient selection for extended hormonal therapy. Methods: A total of 1702 postmenopausal ER þ/HER2 � breast cancer patients from two adjuvant phase III trials (ABCSG6, ABCSG8) treated with 5 years of endocrine therapy participated in this study. The multigene test EndoPredict (EP) and the EPclin score (which combines EP with tumour size and nodal status) were predefined in independent training cohorts. All patients were retrospectively assigned to risk categories based on gene expression and on clinical parameters. The primary…

OncologyCancer Researchmedicine.medical_specialtyAntineoplastic Agents HormonalReceptor ErbB-2AnastrozoleBreast NeoplasmsCell Growth ProcessesAnastrozoleBreast cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsNitrilesClinical endpointHumansMedicineNeoplasm MetastasisProportional Hazards ModelsRandomized Controlled Trials as TopicRetrospective Studiesendocrine therapybusiness.industryProportional hazards modelGene Expression ProfilingCell DifferentiationRetrospective cohort studyTriazolesPrognosismedicine.diseaseSurgeryClinical triallate relapseTamoxifenTreatment OutcomeEditorialClinical Trials Phase III as TopicReceptors EstrogenOncologyClinical StudyHormonal therapyFemaleNeoplasm Recurrence LocalEndoPredictbusinessTamoxifenSignal Transductionmedicine.drugBritish Journal of Cancer
researchProduct